Titre : Chimérisme

Chimérisme : Questions médicales fréquentes

{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Chimérisme : Questions médicales les plus fréquentes", "headline": "Chimérisme : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Chimérisme : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-28", "dateModified": "2025-04-23", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Chimérisme" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Aberrations des chromosomes", "url": "https://questionsmedicales.fr/mesh/D002869", "about": { "@type": "MedicalCondition", "name": "Aberrations des chromosomes", "code": { "@type": "MedicalCode", "code": "D002869", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G05.365.590.175" } } }, "about": { "@type": "MedicalCondition", "name": "Chimérisme", "alternateName": "Chimerism", "code": { "@type": "MedicalCode", "code": "D046528", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Hui Li", "url": "https://questionsmedicales.fr/author/Hui%20Li", "affiliation": { "@type": "Organization", "name": "Department of Biochemistry and Molecular Genetics, School of Medicine, University of Virginia, Charlottesville, VA, United States; Department of Pathology, School of Medicine, University of Virginia, Charlottesville, VA, United States. Electronic address: hl9r@virginia.edu." } }, { "@type": "Person", "name": "Sandeep Singh", "url": "https://questionsmedicales.fr/author/Sandeep%20Singh", "affiliation": { "@type": "Organization", "name": "Department of Pathology, School of Medicine, University of Virginia, Charlottesville, VA, United States." } }, { "@type": "Person", "name": "Hao Zhang", "url": "https://questionsmedicales.fr/author/Hao%20Zhang", "affiliation": { "@type": "Organization", "name": "Institute of Precision Cancer Medicine and Pathology, Jinan University Medical College, Guangzhou, Guangdong, China. haozhang@jnu.edu.cn." } }, { "@type": "Person", "name": "Xinrui Shi", "url": "https://questionsmedicales.fr/author/Xinrui%20Shi", "affiliation": { "@type": "Organization", "name": "Department of Biochemistry and Molecular Genetics, School of Medicine, University of Virginia, Charlottesville, VA, United States." } }, { "@type": "Person", "name": "Yusheng Lin", "url": "https://questionsmedicales.fr/author/Yusheng%20Lin", "affiliation": { "@type": "Organization", "name": "Institute of Precision Cancer Medicine and Pathology, Jinan University Medical College, Guangzhou, Guangdong, China." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Bias reduction improves accuracy and informativity of high-throughput sequencing chimerism assays.", "datePublished": "2023-06-19", "url": "https://questionsmedicales.fr/article/37343694", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.cca.2023.117452" } }, { "@type": "ScholarlyArticle", "name": "Donor chimerism and immune reconstitution following haploidentical transplantation in sickle cell disease.", "datePublished": "2022-12-09", "url": "https://questionsmedicales.fr/article/36569951", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fimmu.2022.1055497" } }, { "@type": "ScholarlyArticle", "name": "Prospects and Potential for Chimerism Analysis after Allogeneic Hematopoietic Stem Cell Transplantation.", "datePublished": "2024-06-06", "url": "https://questionsmedicales.fr/article/38891125", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/cells13110993" } }, { "@type": "ScholarlyArticle", "name": "Evaluation of a quantitative PCR-based method for chimerism analysis of Japanese donor/recipient pairs.", "datePublished": "2022-12-09", "url": "https://questionsmedicales.fr/article/36494422", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-022-25878-9" } }, { "@type": "ScholarlyArticle", "name": "Post-transplant cyclophosphamide and early mixed donor Chimerism in myeloid malignancies; a single-center experience.", "datePublished": "2023-02-24", "url": "https://questionsmedicales.fr/article/36842566", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.trim.2023.101808" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Phénomènes génétiques", "item": "https://questionsmedicales.fr/mesh/D055614" }, { "@type": "ListItem", "position": 3, "name": "Variation génétique", "item": "https://questionsmedicales.fr/mesh/D014644" }, { "@type": "ListItem", "position": 4, "name": "Mutation", "item": "https://questionsmedicales.fr/mesh/D009154" }, { "@type": "ListItem", "position": 5, "name": "Aberrations des chromosomes", "item": "https://questionsmedicales.fr/mesh/D002869" }, { "@type": "ListItem", "position": 6, "name": "Chimérisme", "item": "https://questionsmedicales.fr/mesh/D046528" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Chimérisme - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Chimérisme", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-04-29", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Chimérisme", "description": "Comment diagnostiquer le chimérisme ?\nQuels tests sont utilisés pour le chimérisme ?\nLe chimérisme peut-il être détecté par échographie ?\nQuels signes cliniques peuvent indiquer un chimérisme ?\nLe chimérisme est-il héréditaire ?", "url": "https://questionsmedicales.fr/mesh/D046528?page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Chimérisme", "description": "Quels sont les symptômes du chimérisme ?\nLe chimérisme cause-t-il des douleurs ?\nPeut-on avoir des symptômes sans chimérisme ?\nLe chimérisme affecte-t-il la croissance ?\nY a-t-il des symptômes spécifiques au chimérisme ?", "url": "https://questionsmedicales.fr/mesh/D046528?page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Chimérisme", "description": "Peut-on prévenir le chimérisme ?\nY a-t-il des facteurs de risque pour le chimérisme ?\nLes tests prénataux peuvent-ils détecter le chimérisme ?\nLe chimérisme est-il lié à des pratiques médicales ?\nLes femmes enceintes doivent-elles se méfier du chimérisme ?", "url": "https://questionsmedicales.fr/mesh/D046528?page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Chimérisme", "description": "Comment traiter le chimérisme ?\nLe chimérisme nécessite-t-il une intervention chirurgicale ?\nLes médicaments peuvent-ils aider au chimérisme ?\nY a-t-il des traitements naturels pour le chimérisme ?\nLe suivi médical est-il nécessaire pour le chimérisme ?", "url": "https://questionsmedicales.fr/mesh/D046528?page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Chimérisme", "description": "Quelles complications peuvent survenir avec le chimérisme ?\nLe chimérisme peut-il causer des cancers ?\nComment gérer les complications du chimérisme ?\nLe chimérisme affecte-t-il le système immunitaire ?\nY a-t-il des risques de rejet avec le chimérisme ?", "url": "https://questionsmedicales.fr/mesh/D046528?page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Chimérisme", "description": "Quels sont les facteurs de risque du chimérisme ?\nLe chimérisme est-il plus fréquent chez certaines populations ?\nLes greffes augmentent-elles le risque de chimérisme ?\nLes antécédents médicaux influencent-ils le chimérisme ?\nLe chimérisme est-il lié à des facteurs environnementaux ?", "url": "https://questionsmedicales.fr/mesh/D046528?page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer le chimérisme ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic se fait par analyse génétique, notamment par PCR ou séquençage." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour le chimérisme ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests incluent l'analyse de l'ADN, les tests de compatibilité tissulaire et les marqueurs génétiques." } }, { "@type": "Question", "name": "Le chimérisme peut-il être détecté par échographie ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Non, l'échographie ne peut pas détecter le chimérisme, seul un test génétique est fiable." } }, { "@type": "Question", "name": "Quels signes cliniques peuvent indiquer un chimérisme ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des signes cliniques peuvent inclure des anomalies immunitaires ou des différences phénotypiques." } }, { "@type": "Question", "name": "Le chimérisme est-il héréditaire ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Non, le chimérisme n'est généralement pas héréditaire, il résulte d'événements embryonnaires." } }, { "@type": "Question", "name": "Quels sont les symptômes du chimérisme ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes varient, mais peuvent inclure des anomalies cutanées ou des troubles immunitaires." } }, { "@type": "Question", "name": "Le chimérisme cause-t-il des douleurs ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Le chimérisme en soi ne cause pas de douleurs, mais des complications peuvent en entraîner." } }, { "@type": "Question", "name": "Peut-on avoir des symptômes sans chimérisme ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, de nombreux symptômes peuvent être causés par d'autres conditions médicales." } }, { "@type": "Question", "name": "Le chimérisme affecte-t-il la croissance ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Il peut affecter la croissance si des anomalies génétiques ou hormonales sont présentes." } }, { "@type": "Question", "name": "Y a-t-il des symptômes spécifiques au chimérisme ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des différences de pigmentation ou des anomalies immunitaires peuvent être spécifiques." } }, { "@type": "Question", "name": "Peut-on prévenir le chimérisme ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Le chimérisme ne peut pas être prévenu car il résulte d'événements embryonnaires." } }, { "@type": "Question", "name": "Y a-t-il des facteurs de risque pour le chimérisme ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs de risque incluent des grossesses multiples ou des transfusions sanguines." } }, { "@type": "Question", "name": "Les tests prénataux peuvent-ils détecter le chimérisme ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les tests prénataux standard ne détectent pas le chimérisme, des tests génétiques spécifiques sont nécessaires." } }, { "@type": "Question", "name": "Le chimérisme est-il lié à des pratiques médicales ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines pratiques comme les greffes peuvent augmenter le risque de chimérisme." } }, { "@type": "Question", "name": "Les femmes enceintes doivent-elles se méfier du chimérisme ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Il n'y a pas de mesures préventives spécifiques pour les femmes enceintes concernant le chimérisme." } }, { "@type": "Question", "name": "Comment traiter le chimérisme ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement dépend des symptômes et peut inclure des thérapies immunosuppressives." } }, { "@type": "Question", "name": "Le chimérisme nécessite-t-il une intervention chirurgicale ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Rarement, sauf si des complications graves nécessitent une intervention spécifique." } }, { "@type": "Question", "name": "Les médicaments peuvent-ils aider au chimérisme ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des médicaments immunosuppresseurs peuvent être prescrits pour gérer les symptômes." } }, { "@type": "Question", "name": "Y a-t-il des traitements naturels pour le chimérisme ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de traitements naturels prouvés pour le chimérisme, consultez un médecin." } }, { "@type": "Question", "name": "Le suivi médical est-il nécessaire pour le chimérisme ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un suivi régulier est essentiel pour surveiller les complications potentielles." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec le chimérisme ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des troubles immunitaires, des rejets de greffe ou des cancers." } }, { "@type": "Question", "name": "Le chimérisme peut-il causer des cancers ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines formes de chimérisme peuvent augmenter le risque de cancers spécifiques." } }, { "@type": "Question", "name": "Comment gérer les complications du chimérisme ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "La gestion implique un suivi médical régulier et des traitements adaptés aux symptômes." } }, { "@type": "Question", "name": "Le chimérisme affecte-t-il le système immunitaire ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le chimérisme peut entraîner des dysfonctionnements du système immunitaire." } }, { "@type": "Question", "name": "Y a-t-il des risques de rejet avec le chimérisme ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le rejet peut survenir si des cellules étrangères sont reconnues par le système immunitaire." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque du chimérisme ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les grossesses multiples et les transfusions sanguines sont des facteurs de risque connus." } }, { "@type": "Question", "name": "Le chimérisme est-il plus fréquent chez certaines populations ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Il n'y a pas de données précises, mais les grossesses multiples peuvent augmenter le risque." } }, { "@type": "Question", "name": "Les greffes augmentent-elles le risque de chimérisme ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les greffes d'organes peuvent introduire des cellules étrangères, entraînant un chimérisme." } }, { "@type": "Question", "name": "Les antécédents médicaux influencent-ils le chimérisme ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents de transfusions ou de greffes peuvent augmenter le risque de chimérisme." } }, { "@type": "Question", "name": "Le chimérisme est-il lié à des facteurs environnementaux ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de preuves solides liant le chimérisme à des facteurs environnementaux." } } ] } ] }

Sources (1467 au total)

Bias reduction improves accuracy and informativity of high-throughput sequencing chimerism assays.

Chimerism monitoring by means of high-throughput sequencing of biallelic polymorphisms has shown promising advantages for patient follow-up after hematopoietic stem cell transplantation. Yet, the pres... This paper suggests how preferential allelic observation may lead to method bias, and when and why such bias necessitates the exclusion of markers. It is shown that also markers that remain informativ... Improved design and data analysis of chimerism assays increase the accuracy, applicability, and cost-effectiveness of high-throughput sequencing chimerism assays....

Donor chimerism and immune reconstitution following haploidentical transplantation in sickle cell disease.

We previously reported the initial results of a phase II multicenter transplant trial using haploidentical parental donors for children and aolescents with high-risk sickle cell disease achieving exce... CD34 cells were enriched using the CliniMACS... HLA antibodies were detected in 7 of 11 (64%) evaluable patients but rarely were against donor antigens. Myeloid engraftment was rapid (100%) at a median of 9 days. At 30 days, donor chimerism was 93-... These results suggest that haploidentical transplantation with CD34-enriched cells and peripheral blood mononuclear cell addback results in rapid engraftment, sustained donor chimerism and broad-based...

Post-transplant cyclophosphamide and early mixed donor Chimerism in myeloid malignancies; a single-center experience.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative option for high-risk myeloid malignancies. Post-transplant cyclophosphamide (PT-Cy) has proven to be effective ... We investigated the impact of PT-Cy on early MC (EMC) and disease relapse in patients with a myeloid malignancy post allo-HSCT.... This retrospective single-center study included patients that underwent allo-HSCT between 2015 and 2021. Patient and disease characteristics were collected from the electronic health records. EMC was ... A total of 144 patient that received an allo-HSCT were included in the study. One hundred and eight (75%) patients received PT-Cy as part of the GVHD prophylaxis regimen. The majority underwent allo-H... Our study shows that PT-Cy was associated with an increased risk of EMC. The predictive value of EMC for relapse remains unclear and may depend on the underlying disease, which should be validated in ...

Role of HLA typing and chimerism analysis in post-liver transplantation GVHD in pediatrics: A systematic review.

GVHD is a well-documented complication after liver transplantation. GVHD occurs when donor immune cells mount a destructive immune response against host cells. The rarity of the GVHD complication and ... In this systematic review, we assessed relevant literature to better understand the utilization of HLA typing and chimerism analysis in liver transplantation. We mainly focused on their importance in ... A total of 18 articles reported 21 cases of GVHD after liver transplantation in pediatrics. Generally, there is a consensus on the advantage of HLA typing and chimerism analysis in confirming the diag... Further studies are required to assess the incidence of GVHD post-LT and to determine the impact of HLA typing and chimerism analysis in assessing the risk, early determination of GVHD incidence, and ...

The predictive value of T-cell chimerism for disease relapse after allogeneic hematopoietic stem cell transplantation.

Chimerism is closely correlated with disease relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, chimerism rate is dynamic changes, and the sensitivity of different ... To investigate the predictive value of distinct chimerism for relapse, we measured bone marrow (BM), peripheral blood (PB), and T-cell (isolated from BM) chimerism in 178 patients after allo-HSCT.... Receiver operating characteristic (ROC) curve showed that T-cell chimerism was more suitable to predict relapse after allo-HSCT compared with PB and BM chimerism. The cutoff value of T-cell chimerism ... We recommend constant monitoring T-cell chimerism at 2, 3, 6, and 9 months after allo-HSCT to predict relapse....

Chimerism monitoring using biallelic single nucleotide or insertion/deletion polymorphisms: How many markers to screen?

Chimerism monitoring by means of high-throughput sequencing or quantitative PCR of biallelic single nucleotide and insertion/deletion polymorphisms has shown potential for improved patient care when c... A simulation framework accounting for marker minor allele frequencies, the number of markers screened, marker allelic constellations and donor-recipient relatedness was constructed. The framework was ... Empirical clinical data confirm the validity of the simulation framework. With guidelines suggesting to monitor at least three informative markers, we demonstrate that, for optimized assays, at least ... Currently used chimerism assays often screen too little or too many markers, leaving room for optimization. Through support of the simulation framework here introduced and validated, more informative,...